Compare USCB & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | USCB | ENTA |
|---|---|---|
| Founded | 2002 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 335.0M | 374.6M |
| IPO Year | 2021 | 2012 |
| Metric | USCB | ENTA |
|---|---|---|
| Price | $18.13 | $15.09 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $23.00 | $20.40 |
| AVG Volume (30 Days) | 45.9K | ★ 107.0K |
| Earning Date | 04-23-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.72% | N/A |
| EPS Growth | 7.26 | ★ 29.93 |
| EPS | ★ 1.33 | N/A |
| Revenue | N/A | ★ $102,814,000.00 |
| Revenue This Year | $26.46 | $7.76 |
| Revenue Next Year | $9.67 | N/A |
| P/E Ratio | $13.65 | ★ N/A |
| Revenue Growth | N/A | ★ 16.48 |
| 52 Week Low | $15.57 | $4.96 |
| 52 Week High | $20.79 | $17.15 |
| Indicator | USCB | ENTA |
|---|---|---|
| Relative Strength Index (RSI) | 35.38 | 65.72 |
| Support Level | $17.74 | $12.91 |
| Resistance Level | $18.70 | $15.37 |
| Average True Range (ATR) | 0.59 | 0.70 |
| MACD | -0.16 | 0.11 |
| Stochastic Oscillator | 6.28 | 88.52 |
USCB Financial Holdings Inc is a bank holding company. Through its banking subsidiary, it offers relationship-based banking products, services, and solutions to a diverse set of clients in the local markets it operates in and international clients with U.S. banking needs. The Group's products and services offerings mainly include traditional deposit products, including commercial and consumer checking accounts, money market deposit accounts, savings accounts, etc.; e-banking services; title insurance policies for real estate transactions; and a variety of lending products such as small business loans, commercial real estate loans, business credit cards, etc.; and others. Geographically, its primary banking market is South Florida.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.